You are here

Farxiga

AstraZeneca calls victory in CV study, but will payers feel the same?

Biopharma Dive

Mon, 11/12/18 - 11:30 pm

AstraZeneca's diabetes drug curbs heart failure, kidney risks

Yahoo/Reuters

Sun, 11/11/18 - 09:14 pm

Farxiga Meets One Primary Endpoint in Large Ph III Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes

CP Wire

Mon, 09/24/18 - 10:01 am

clinical trials

type 2 diabetes

cardiovascular disease

Farxiga Meets One Primary Endpoint in Large Ph III Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes

Mon, 09/24/18 - 09:36 am

AstraZeneca touts a fresh cut of Farxiga data targeting diabetes patients with chronic kidney disease

Endpoints

Tue, 03/20/18 - 09:38 am

chronic kidney disease

J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefits

Fierce Pharma

Fri, 11/24/17 - 09:23 am

Boehringer Ingelheim

ADA: Merck, Pfizer notch success, but late with SGLT-2 data

BioPharma Dive

Tue, 06/13/17 - 12:15 pm

SGLT2 inhibitor

Boehringer Ingelheim

What to Expect from AstraZeneca’s Farxiga in 2017

Market Realist

Thu, 03/23/17 - 09:28 am

Merck and Pfizer prep for battle with SGLT2, combo diabetes filings

Fierce Pharma

Mon, 03/13/17 - 10:18 am

SGLT2 inhibitor

Boehringer Ingelheim

FDA warns of kidney risks for diabetes drugs from Janssen, AstraZeneca

BioPharma Dive

Tue, 06/14/16 - 07:27 pm

AZ tallies a pair of Farxiga wins with new data from renal, potassium analyses

Fierce Pharma

Mon, 06/13/16 - 07:12 pm

FDA warns on newer class of type 2 diabetes drugs

Yahoo/Reuters

Sat, 05/16/15 - 02:04 pm

type 2 diabetes

Boehringer Ingelheim

SGLT2 inhibitor

Will Diabetes Drugs Enter The Anti-Obesity Space?

Seeking Alpha

Mon, 12/8/14 - 08:30 am

Arena Pharmaceuticals

Pages